Experimental combo targets rare childhood brain cancer
NCT ID NCT02774421
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether a drug called trastuzumab, given with an immune booster (GM-CSF), can safely reach and treat recurrent ependymoma in children. Ten children with this rare brain tumor will receive the drugs to see if the treatment is safe and can be detected in the tumor. The goal is to gather early data for future, larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab (a cancer drug) and GM-CSF (an immune booster)
- What this could lead to
- If it works, this could point toward a new treatment option for children with recurrent ependymoma, a rare brain tumor.
- What could go wrong
- This is a very early, small pilot study with only 10 participants. It is designed mainly to check safety and whether the drug reaches the tumor, not to prove effectiveness. The treatment may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTERIOR FOSSA EPENDYMOMA (PFEPN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States